Does oxybutynin reduce hot flash symptoms in men receiving ADT for prostate cancer?
What was 5 year local control for oligometastatic lesions treated with SBRT in the SABR 5 trial?
What tumor characteristic significantly increases the risk of fatal hemorrhage independent of bronchial dose for those receiving SBRT for ultracentral lung tumors?
In IMMUNEBOOST-HPV, did neoadjuvant nivolumab improve PFS among those receiving chemoradiation for p16 positive HNSCC?
Answers
Yes, at doses of 2.5mg BID or 5mg BID for those reporting at least 28 hot flashes per week.
85%. Long term follow up showed 5 year OS of 58.6% and PFS of 20.3%.
Bronchial tumor compression. Regardless of dose, bronchial compression had a baseline risk of 10% for hemorrhage–equivalent to a D0.31cc of 107 Gy. At a dose of just 58 Gy EQD2(3) in the presence of bronchial compression, the risk of grade 5 hemorrhage was 20%.
No. The trial was negative as fewer patients in the induction nivo arm received at least 200mg total of concurrent cisplatin. | QuadShot News
What was 5 year local control for oligometastatic lesions treated with SBRT in the SABR 5 trial?
What tumor characteristic significantly increases the risk of fatal hemorrhage independent of bronchial dose for those receiving SBRT for ultracentral lung tumors?
In IMMUNEBOOST-HPV, did neoadjuvant nivolumab improve PFS among those receiving chemoradiation for p16 positive HNSCC?
Answers
Yes, at doses of 2.5mg BID or 5mg BID for those reporting at least 28 hot flashes per week.
85%. Long term follow up showed 5 year OS of 58.6% and PFS of 20.3%.
Bronchial tumor compression. Regardless of dose, bronchial compression had a baseline risk of 10% for hemorrhage–equivalent to a D0.31cc of 107 Gy. At a dose of just 58 Gy EQD2(3) in the presence of bronchial compression, the risk of grade 5 hemorrhage was 20%.
No. The trial was negative as fewer patients in the induction nivo arm received at least 200mg total of concurrent cisplatin. | QuadShot News